foxo4-dri senolytic peptide human trial 2024 2025 Targeting Senescence: A Review of Senolytics and Senomorphics in Anti-Aging Interventions FOXO4-DRI: Human Trial Status, Cancer
FOXO4 DRI: Human Trial Status, Cancer Research & Senolytic Data Buy FOXO4 DRI Peptide (Proxofim) 10mg BiotechPeptides The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4 DRI Nature Communications Senescent cells as a target for anti aging interventions: From senolytics to immune therapies PMC Molecular modelling of the FOXO4 TP53 interaction to design senolytic peptides for the elimination of senescent cancer cells eBioMedicine
Pay in 4 interest-free payments of $5.35 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 6 - Aug 11




